Brief: Appili Therapeutics Enrolls Last Patient In Phase 3 Trial Of Oral Avigan/Reeqonus For Treatment Of Mild-To-Moderate COVID-19
23/09/2021 12:49
Sept 23 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES LAST PATIENT ENROLLED IN
PHASE 3
TRIAL OF ORAL AVIGAN®/REEQONUS™ FOR THE TREATMENT OF
MILD-TO-MODERATE COVID-19
* APPILI THERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE DATA
FROM
TRIAL IN APPROXIMATELY 60 DAYS
Source text for Eikon: ID:nBw6GMvdDa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez